MY010

Indicaton

Human antibody product against major birch and birch-related allergens to treat pollen allergy via
anti-allergen therapy.

Therapeutic indications

Type of product

Antibody

Table

Phase

Discovery
Partnering status

Not partnered

You may also be interested in

3D CoSeedis in chip Assays

Preclinical 3D Study models for oncology and neurology.

TOP-N53, TOP-V122, TOP-M119 and TOP-N44

TOPADUR has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases as chronic wounds, glaucoma, colorectal cancer, hair loss and skin aging.

Phase I started

POL6014

Cystic fibrosis (CF) and other neutrophilic pulmonary diseases

Phase I started